Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Synthetic Biologics Names Commercial Strategy VP | Contract Pharma

What are you searching for?

Sign in
Breaking News, Promotions & Moves

Synthetic Biologics Names Commercial Strategy VP

25-year Wyeth veteran brings extensive experience

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Lewis Barrett has been named senior vice president of commercial strategy at Synthetic Biologics, Inc. Mr. Barrett previously served as senior vice president of Commercial Strategy at Synthetic Biologics and served as an advisor to the company since September 2012. Mr. Barrett provides strategic consultation to the global life sciences with a focus on brand and lifecycle strategy, business development, and strategic communications through LL Barrett Biopharmaceutical Consulting, LLC.
 
Prior to joining the company, Mr. Barrett served as assistant vice president of Established Products at Pfizer and vice president and global business manager of Infectious Diseases at Wyeth Pharmaceuticals and brings expertise in the development, commercialization and launch of infectious disease product candidates. Mr. Barrett successfully led, co-chaired or served on teams that focused on infectious diseases, oncology, transplantation, and hemophilia during his 25 years at Wyeth (acquired by Pfizer in 2009).
 
Jeffrey Riley, chief executive officer at Synthetic Biologics, said, “We are pleased to welcome Lew to the Synthetic Biologics’ team and expect that his extensive experience in the development and commercialization of anti-infectives will be vital to the company as we develop SYN-004 for the prevention of C. difficile infections and monoclonal antibody therapies for the treatment of Pertussis and Acinetobacter infections.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters